INDIANA (WFIE) – Attorney General Todd Rokita says he’s filed a new lawsuit against Indianapolis-based Eli Lilly and Company in an effort to lower insulin prices and improve healthcare affordability for Indiana residents.
The action joins Indiana’s prior lawsuit against other insulin manufacturers and pharmacy benefit managers.
The lawsuit claims there have been deceptive market practices.
Officials say nearly 700,000 Indiana residents have been diagnosed with diabetes, with millions more being pre-diabetic.
Experts say diabetes is the leading cause of blindness, kidney failure, and lower-limb amputations, and a major cause of death in Indiana despite effective treatments being available.
“Pharmaceutical companies should not take advantage of Hoosiers or any other American—this includes Lilly, regardless of its Indiana roots,” Rokita said. “For two years, I attempted to resolve this matter with them amicably and without litigation—an effort not required by the state and one not afforded to Lilly’s out-of-state competitors.”
Rokita said Eli Lilly maintains the largest market share for insulin, and he said Indiana intends to be added to ongoing multistate litigation.
The lawsuit accuses Eli Lilly of participating in a scheme with other insulin manufacturers and pharmacy benefit managers that dramatically inflated insulin prices over the past decade by more than 1000% despite low manufacturing costs estimated at just a few dollars per vial.
Rokita said prior accountability efforts, including Indiana’s earlier lawsuit, have prompted manufacturers—including Eli Lilly—to substantially reduce prices and introduce $35 monthly out-of-pocket caps for many patients.
Read the lawsuit here.
Rokita has also taken action against pharmaceutical companies concerning EpiPen prices. He says they’ve increased by 600% while deceiving Indiana consumers.
Copyright 2026 WFIE. All rights reserved.